However, the role of mTOR clinical targeting agents (including Rapalogs such as Temsirolimus (TEMS) [7]) in the regulation of mitochondrial networks and LD biogenesis has not yet been investigated in ccRCC. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.